Bystander cytotoxicity in human medullary thyroid carcinoma cells mediated by fusion yeast cytosine deaminase and 5-fluorocytosine

Cancer Letters

Volumn 311, Issue 1, 2011, Pages 101-112

  Kucerova, Lucia ^a   Matuskova, Miroslava ^a   Hlubinova, Kristina ^a   Bohovic, Roman ^a   Feketeova, Lucia ^b   Janega, Pavol ^b,c   Babal, Pavel ^b   Poturnajova, Martina ^a  

^a CANCER RESEARCH INSTITUTE   (Slovakia)

^b Comenius University in Bratislava ^*  (Slovakia)

^c INSTITUTE OF CHEMISTRY   (Slovakia)

Author keywords

5 Fluorocytosine; Bystander cytotoxicity; Cytosine deaminase; Gene directed enzyme prodrug therapy; Human medullary thyroid carcinoma; Suicide effect

Indexed keywords

ADENOSINE DEAMINASE; FLUCYTOSINE; FLUOROURACIL; HYBRID PROTEIN; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BYSTANDER EFFECT; CANCER GENE THERAPY; CANCER GROWTH; CARCINOMA CELL; CELL PROLIFERATION; COCULTURE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; FEMALE; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MESENCHYME CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; STROMA CELL; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; YEAST;

ANIMALS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; CYTOSINE DEAMINASE; FEMALE; FLUCYTOSINE; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICE, NUDE; RANDOM ALLOCATION; THYROID NEOPLASMS; TRANSDUCTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052163915     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.07.014     Document Type: Article

References (42)

1. Kondo T., Ezzat S., Asa S.L. Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 2006, 6:292-306.
2. D. Tai, D. Poon, Molecular and other novel advances in treatment of metastatic epithelial and medullary thyroid cancers, J. Oncol. 2010 (2010).
3. Zhu W., Hai T., Ye L., Cote G.J. Medullary thyroid carcinoma cell lines contain a self-renewing CD133+ population that is dependent on ret proto-oncogene activity. J. Clin. Endocrinol. Metab. 2010, 95:439-444.
4. Berger C.L., de Bustros A., Roos B.A., Leong S.S., Mendelsohn G., Gesell M.S., Baylin S.B. Human medullary thyroid carcinoma in culture provides a model relating growth dynamics, endocrine cell differentiation, and tumor progression. J. Clin. Endocrinol. Metab. 1984, 59:338-343.
5. Sugawara M., Geffner D.L., Martinez D., Hershman J.M. Novel treatment of medullary thyroid cancer. Curr. Opin. Endocrinol. Diabetes Obes. 2009, 16:367-372.
6. Pennell N.A., Daniels G.H., Haddad R.I., Ross D.S., Evans T., Wirth L.J., Fidias P.H., Temel J.S., Gurubhagavatula S., Heist R.S., Clark J.R., Lynch T.J. A phase II study of gefitinib in patients with advanced thyroid cancer. Thyroid 2008, 18:317-323.
7. Salvatore G., De Falco V., Salerno P., Nappi T.C., Pepe S., Troncone G., Carlomagno F., Melillo R.M., Wilhelm S.M., Santoro M. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin. Cancer Res. 2006, 12:1623-1629.
8. Lam E.T., Ringel M.D., Kloos R.T., Prior T.W., Knopp M.V., Liang J., Sammet S., Hall N.C., Wakely P.E., Vasko V.V., Saji M., Snyder P.J., Wei L., Arbogast D., Collamore M., Wright J.J., Moley J.F., Villalona-Calero M.A., Shah M.H. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J. Clin. Oncol. 2010, 28:2323-2330.
9. Carlomagno F., Vitagliano D., Guida T., Ciardiello F., Tortora G., Vecchio G., Ryan A.J., Fontanini G., Fusco A., Santoro M. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res. 2002, 62:7284-7290.
10. Ezzat S., Huang P., Dackiw A., Asa S.L. Dual inhibition of RET and FGFR4 restrains medullary thyroid cancer cell growth. Clin. Cancer Res. 2005, 11:1336-1341.
11. Carlomagno F., Anaganti S., Guida T., Salvatore G., Troncone G., Wilhelm S.M., Santoro M. BAY 43-9006 inhibition of oncogenic RET mutants. J. Natl. Cancer Inst. 2006, 98:326-334.
12. Milano A., Chiofalo M.G., Basile M., Salzano de Luna A., Pezzullo L., Caponigro F. New molecular targeted therapies in thyroid cancer. Anticancer Drugs 2006, 17:869-879.
13. Labidi S.I., Gravis G., Tarpin C., Brun V., Viens P. Medullary thyroid cancer treated by capecitabine. Anticancer Drugs 2007, 18:831-834.
14. Nishihara E., Nagayama Y., Narimatsu M., Namba H., Watanabe M., Niwa M., Yamashita S. Treatment of thyroid carcinoma cells with four different suicide gene/prodrug combinations in vitro. Anticancer Res. 1998, 18:1521-1525.
15. Messina M., Robinson B.G. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat. Clin. Pract. Endocrinol. Metab. 2007, 3:290-301.
16. Dwyer R.M., Khan S., Barry F.P., O'Brien T., Kerin M.J. Advances in mesenchymal stem cell-mediated gene therapy for cancer. Stem Cell Res. Ther. 2010, 1:25.
17. Dwyer R.M., Kerin M.J. Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets?. Hum. Gene Ther. 2010, 21:1506-1512.
18. Myers T.J., Granero-Molto F., Longobardi L., Li T., Yan Y., Spagnoli A. Mesenchymal stem cells at the intersection of cell and gene therapy. Expert Opin. Biol. Ther. 2010, 10:1663-1679.
19. Kucerova L., Altanerova V., Matuskova M., Tyciakova S., Altaner C. Adipose tissue-derived human mesenchymal stem cells mediated prodrug cancer gene therapy. Cancer Res. 2007, 67:6304-6313.
20. Kucerova L., Matuskova M., Pastorakova A., Tyciakova S., Jakubikova J., Bohovic R., Altanerova V., Altaner C. Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. J. Gene Med. 2008, 10:1071-1082.
21. Matuskova M., Hlubinova K., Pastorakova A., Hunakova L., Altanerova V., Altaner C., Kucerova L. HSV-tk expressing mesenchymal stem cells exert bystander effect on human glioblastoma cells. Cancer Lett. 2010, 290:58-67.
22. Altanerova V., Horvathova E., Matuskova M., Kucerova L., Altaner C. Genotoxic damage of human adipose-tissue derived mesenchymal stem cells triggers their terminal differentiation. Neoplasma 2009, 56:542-547.
23. Cavarretta I.T., Altanerova V., Matuskova M., Kucerova L., Culig Z., Altaner C. Adipose tissue-derived mesenchymal stem cells expressing prodrug-converting enzyme inhibit human prostate tumor growth. Mol. Ther. 2010, 18:223-231.
24. Kucerova L., Matuskova M., Hlubinova K., Altanerova V., Altaner C. Tumor cell behaviour modulation by mesenchymal stromal cells. Mol. Cancer 2010, 9:129.
25. Kucerova L., Kovacovicova M., Polak S., Bohac M., Fedeles J., Palencar D., Matuskova M. Interaction of human adipose tissue-derived mesenchymal stromal cells with breast cancer cells. Neoplasma 2011, 58:361-370.
26. Zhao D., Najbauer J., Garcia E., Metz M.Z., Gutova M., Glackin C.A., Kim S.U., Aboody K.S. Neural stem cell tropism to glioma: critical role of tumor hypoxia. Mol. Cancer Res. 2008, 6:1819-1829.
27. Nakamura A., Kakudo K., Watanabe K. Establishment of a new human thyroid medullary carcinoma cell line. Morphological studies. Virchows Arch B - Cell Pathol. Incl. Mol. Pathol. 1987, 53:332-335.
28. Pfragner R., Hofler H., Behmel A., Ingolic E., Walser V. Establishment and characterization of continuous cell line MTC-SK derived from a human medullary thyroid carcinoma. Cancer Res. 1990, 50:4160-4166.
29. Tanaka K., Baylin S.B., Nelkin B.D., Testa J.R. Cytogenetic studies of a human medullary thyroid carcinoma cell line. Cancer Genet. Cytogenet. 1987, 25:27-35.
30. Abemayor E., Sidell N., Juillard G. Human medullary thyroid carcinoma. Initial characterization and in vitro differentiation of two new cell lines. Arch. Otolaryngol. Head Neck Surg. 1989, 115:478-483.
31. Pfragner R., Wirnsberger G.H., Ingolic E., Niederle B. Medullary thyroid carcinomas in cell culture - models for future therapies. Wien. Klin. Wochenschr. 2002, 114:279-283.
32. Kaczirek K., Schindl M., Weinhausel A., Scheuba C., Passler C., Prager G., Raderer M., Hamilton G., Mittlbock M., Siegl V., Pfragner R., Niederle B. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J. Clin. Endocrinol. Metab. 2004, 89:2397-2401.
33. Behr T.M., Gratz S., Markus P.M., Dunn R.M., Hufner M., Schauer A., Fischer M., Munz D.L., Becker H., Becker W. Anti-carcinoembryonic antigen antibodies versus somatostatin analogs in the detection of metastatic medullary thyroid carcinoma: are carcinoembryonic antigen and somatostatin receptor expression prognostic factors?. Cancer 1997, 80:2436-2457.
34. Zatelli M.C., Luchin A., Piccin D., Tagliati F., Bottoni A., Vignali C., Bondanelli M., degli Uberti E.C. Cyclooxygenase-2 inhibitors reverse chemoresistance phenotype in medullary thyroid carcinoma by a permeability glycoprotein-mediated mechanism. J. Clin. Endocrinol. Metab. 2005, 90:5754-5760.
35. Szakacs G., Paterson J.K., Ludwig J.A., Booth-Genthe C., Gottesman M.M. Targeting multidrug resistance in cancer. Nat. Rev. Drug. Discov. 2006, 5:219-234.
36. Hirschmann-Jax C., Foster A.E., Wulf G.G., Goodell M.A., Brenner M.K. A distinct "side population" of cells in human tumor cells: implications for tumor biology and therapy. Cell Cycle 2005, 4:203-205.
37. Frank N.Y., Pendse S.S., Lapchak P.H., Margaryan A., Shlain D., Doeing C., Sayegh M.H., Frank M.H. Regulation of progenitor cell fusion by ABCB5 P-glycoprotein, a novel human ATP-binding cassette transporter. J. Biol. Chem. 2003, 278:47156-47165.
38. Portsmouth D., Hlavaty J., Renner M. Suicide genes for cancer therapy. Mol. Aspects Med. 2007, 28:4-41.
39. Klopp A.H., Gupta A., Spaeth E., Andreeff M., Marini F. Concise review: dissecting a discrepancy in the literature: do mesenchymal stem cells support or suppress tumor growth?. Stem Cells 2011, 29:11-19.
40. Scarpino S., Stoppacciaro A., Ballerini F., Marchesi M., Prat M., Stella M.C., Sozzani S., Allavena P., Mantovani A., Ruco L.P. Papillary carcinoma of the thyroid: hepatocyte growth factor (HGF) stimulates tumor cells to release chemokines active in recruiting dendritic cells. Am. J. Pathol. 2000, 156:831-837.
41. Uchibori R., Okada T., Ito T., Urabe M., Mizukami H., Kume A., Ozawa K. Retroviral vector-producing mesenchymal stem cells for targeted suicide cancer gene therapy. J. Gene Med. 2009, 11:373-381.
42. Nyati M.K., Sreekumar A., Li S., Zhang M., Rynkiewicz S.D., Chinnaiyan A.M., Rehemtulla A., Lawrence T.S. High and selective expression of yeast cytosine deaminase under a carcinoembryonic antigen promoter-enhancer. Cancer Res. 2002, 62:2337-2342.